Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...

Pluvicto is designed to seek out and bind to cancer cells that express PSMA. Once attached, it delivers a small, targeted dose of radiation directly to the cancer cells — killing them while ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the ...

Pluvicto first got FDA approval on March 23, 2022, but this new expanded approval triples the number of patients eligible to receive the drug, according to a Novartis press release.

Pluvicto is marketed and sold by Novartis and generated sales of $1.39 billion in 2024. ATNM-400 is a highly innovative, first-in-class prostate cancer candidate in comparison to Pluvicto and the ...

Twenty years later, the Maimonides Cancer Center spans 18 oncology specialties, from breast and lung cancer to prostate and ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage ...

Pluvicto™ is emblematic of the overarching goal he has set for his career. “My work has always been driven by the goal of reducing suffering and mortality. The most recent leg of this journey started ...

Pluvicto pushes earlier in prostate cancer play. From my colleague Allison DeAngelis: Just a couple of months after getting a new approval for its blockbuster prostate cancer drug Pluvicto ...

Pluvicto was recently approved by the FDA for men whose prostate cancer has not responded to standard treatments. It works by finding and attacking cancer cells while leaving healthy cells alone, ...